CAG/CTG Repeat-Binding Compounds for Defective mRNA Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for genetic diseases associated with CAG or CTG trinucleotide repeat sequences, such as myotonic dystrophy type 1, spinocerebellar ataxia, Huntington's disease, and others, lack a cure that can stop or reverse the progression of the diseases, primarily due to the overproduction and aggregation of defective mRNA leading to cellular dysfunction.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that selectively bind to CAG or CTG trinucleotide repeat sequences in target genes, recruiting regulatory molecules to modulate gene expression and counteract the production of defective mRNA, thereby reducing disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for genetic diseases with CAG or CTG trinucleotide repeat sequences, then symptom management is provided, but the progression of the disease cannot be stopped or reversed
Solution Approach 1:
The patent applies this principle by using antisense oligonucleotides that specifically bind to the defective mRNA containing expanded CAG or CTG trinucleotide repeats. The harmful defective mRNA is converted into a target for therapeutic intervention, where the oligonucleotides recruit RNA-binding proteins to modulate gene expression and reduce the production of toxic mRNA aggregates, thereby stopping or reversing disease progression
Solution Approach 2:
The patent employs antisense oligonucleotides as intermediary molecules that bridge the defective mRNA and regulatory RNA-binding proteins. These oligonucleotides serve as mediators by binding to specific sequences in the defective mRNA and recruiting endogenous RNA-binding proteins to the target site, enabling modulation of gene expression without directly eliminating the defective mRNA
2Reliability
If chimeric heterocyclic polyamide compounds are developed to bind CAG or CTG trinucleotide repeat sequences, then gene expression can be modulated, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic compound into distinct functional modules: a heterocyclic core structure that provides DNA-binding specificity, and polyamide segments that enable sequence-specific recognition of CAG or CTG repeats. This modular architecture allows the complex compound to be designed and synthesized systematically while maintaining precise binding affinity and selectivity for target gene sequences
Solution Approach 2:
The patent employs composite material principles by creating chimeric molecules that combine heterocyclic chemical structures with polyamide sequences. This composite design integrates the stability and binding affinity of heterocyclic compounds with the sequence-specific recognition capabilities of polyamides, enabling the single molecule to simultaneously achieve both stable binding and precise target recognition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the occurrence, severity, or frequency of symptoms associated with these genetic diseases by modulating the expression of defective target genes, providing a potential cure or significant disease progression halt.
Implementation Method 1
chimeric heterocyclic polyamide compounds that selectively bind to CAG or CTG trinucleotide repeat sequences in target genes
Data Source
AI summary
The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2b, tbp, htt, jph3, ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.